Literature DB >> 10885737

Status epilepticus: risk factors and complications.

N B Fountain1.   

Abstract

Status epilepticus is common and associated with significant mortality and complications. It affects approximately 50 patients per 100,000 population annually and recurs in >13%. History of epilepsy is the strongest single risk factor for generalized convulsive status epilepticus. More than 15% of patients with epilepsy have at least one episode of status epilepticus and low antiepileptic drug levels are a potentially modifiable risk factor. Other risks include young age, genetic predisposition, and acquired brain insults. Fever is a very common risk in children, as is stroke in adults. Mortality rates are 15% to 20% in adults and 3% to 15% in children. Acute complications result from hyperthermia, pulmonary edema, cardiac arrhythmias, and cardiovascular collapse. Long-term complications include epilepsy (20% to 40%), encephalopathy (6% to 15%), and focal neurologic deficits (9% to 11%). Neuronal injury leading to temporal lobe epilepsy is probably mediated by excess excitation via activation of the N-methyl-D-aspartate (NMDA) subtype of glutamate receptors and consequent elevated intracellular calcium that causes acute necrosis and delayed apoptotic cell death. Some forms of nonconvulsive status epilepticus may also lead to neuronal injury by this mechanism, but others may not. Based on clinical and experimental observations, complex partial status epilepticus is more likely to result in neuronal injury similar to generalized convulsive status epilepticus. Absence status epilepticus is much less likely to result in neuronal injury, and complications because it may be mediated primarily through excess inhibition. Future research strategies to prevent complications of status epilepticus include the study of new drugs (including NMDA antagonists, new drug delivery systems, and drug combinations) to stop seizure activity and prevent acute and delayed neuronal injury that leads to the development of epilepsy.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10885737     DOI: 10.1111/j.1528-1157.2000.tb01521.x

Source DB:  PubMed          Journal:  Epilepsia        ISSN: 0013-9580            Impact factor:   5.864


  50 in total

Review 1.  Seizure prediction and its applications.

Authors:  Leon D Iasemidis
Journal:  Neurosurg Clin N Am       Date:  2011-10       Impact factor: 2.509

Review 2.  Benzodiazepine-refractory status epilepticus: pathophysiology and principles of treatment.

Authors:  Jerome Niquet; Roger Baldwin; Lucie Suchomelova; Lucille Lumley; David Naylor; Roland Eavey; Claude G Wasterlain
Journal:  Ann N Y Acad Sci       Date:  2016-07-08       Impact factor: 5.691

3.  Recent and future advances in the treatment of status epilepticus.

Authors:  Felix Rosenow; Susanne Knake
Journal:  Ther Adv Neurol Disord       Date:  2008-07       Impact factor: 6.570

Review 4.  Diffusion-weighted imaging of acute excitotoxic brain injury.

Authors:  Toshio Moritani; Wendy R K Smoker; Yutaka Sato; Yuji Numaguchi; Per-Lennart A Westesson
Journal:  AJNR Am J Neuroradiol       Date:  2005-02       Impact factor: 3.825

5.  Increased Superoxide Dismutase 2 by Allopregnanolone Ameliorates ROS-Mediated Neuronal Death in Mice with Pilocarpine-Induced Status Epilepticus.

Authors:  Inja Cho; Won-Joo Kim; Hyun-Woo Kim; Kyoung Heo; Byung In Lee; Yang-Je Cho
Journal:  Neurochem Res       Date:  2018-05-31       Impact factor: 3.996

6.  Status epilepticus.

Authors:  Panayiotis N Varelas; Marek A Mirski
Journal:  Curr Neurol Neurosci Rep       Date:  2009-11       Impact factor: 5.081

7.  Phenytoin, levetiracetam, and pregabalin in the acute management of refractory status epilepticus in patients with brain tumors.

Authors:  Christa B Swisher; Meghana Doreswamy; Krista J Gingrich; James J Vredenburgh; Brad J Kolls
Journal:  Neurocrit Care       Date:  2012-02       Impact factor: 3.210

Review 8.  Differential diagnosis of cerebral hemispheric pathology: multimodal approach.

Authors:  T Moritani; W R K Smoker; H K Lee; Y Sato
Journal:  Clin Neuroradiol       Date:  2011-04-29       Impact factor: 3.649

9.  Status epilepticus: Using antioxidant agents as alternative therapies.

Authors:  Liliana Carmona-Aparicio; Cecilia Zavala-Tecuapetla; María Eva González-Trujano; Aristides Iii Sampieri; Hortencia Montesinos-Correa; Leticia Granados-Rojas; Esaú Floriano-Sánchez; Elvia Coballase-Urrutía; Noemí Cárdenas-Rodríguez
Journal:  Exp Ther Med       Date:  2016-08-23       Impact factor: 2.447

10.  Time course and mechanism of hippocampal neuronal death in an in vitro model of status epilepticus: role of NMDA receptor activation and NMDA dependent calcium entry.

Authors:  Laxmikant S Deshpande; Jeffrey K Lou; Ali Mian; Robert E Blair; Sompong Sombati; Elisa Attkisson; Robert J DeLorenzo
Journal:  Eur J Pharmacol       Date:  2008-02-05       Impact factor: 4.432

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.